Shinobi announced their $51M Series A funding
Shinobi Therapeutics, company developing new class of immune evasive iPS-T cell therapies, announced their launch and $51M Series A funding.

Shinobi Therapeutics, the biotechnology company developing a new class of immune evasive iPS-T cell therapies, announced their launch and $51M Series A funding.

Shinobi has created a new allogeneic CD8αβ iPS-T cell platform that demonstrates comprehensive immune evasion from all arms of the immune system based on the research of scientific co-founders Shin Kaneko, M.D., Ph.D., at Kyoto University and Tobias Deuse, MD, at University of California, San Francisco.

 

To learn more about the company and its unique Katana platform click the link below

https://www.prnewswire.com/news-releases/shinobi-therapeutics-launches-with-completion-of-51m-series-a-to-advance-hypoimmune-ips-t-cell-therapy-platform-302012188.html?tc=eml_cleartimeLearn more at: www.shinobitx.com

シェア

本ウェブサイトに記載されている情報は、ベンチャーキャピタル投資を求める起業家や企業に資する目的においてのみ提供されています。Eight Roadsは、投資助言サービスを提供することを申し出ているものではなく、また証券取引に関与することを申し出ているものでもありません。